- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We’re Reading: Amazon Care to Shut Down; Rise in Youth T2D Diagnoses; Revealing Pressure on FDA Authorization Decisions
Amazon will shut down its telehealth venture Amazon Care by the end of 2022; youth type 2 diabetes (T2D) diagnoses rose by 77% in the first year of the COVID-19 pandemic; officials during Donald Trump’s presidency tried to push for the FDA reauthorization of a discredited COVID-19 treatment.
Amazon Care to Shut Down by End of 2022
Amazon on Wednesday announced plans to shut down its telehealth venture Amazon Care by the end of 2022, STAT News reported. This announcement comes only a month after news of Amazon’s plan to acquire One Medical for $3.9 billion, and will not affect other Amazon health care projects. According to Neil Lindsay, Amazon Health Services leader, the effort “was not a complete enough offering for the large enterprise customers we have been targeting, and wasn’t going to work long-term.”
Rise in New T2D Cases During COVID-19 Pandemic
During the first year of the COVID-19 pandemic, the number of new type 2 diabetes (T2D) diagnoses among US youth rose by 77%, CIDRAP News reported. A study published in Journal of Pediatrics looked at health records of 3113 youth aged between 8 and 21 years who had COVID-19. It showed that new cases of T2D increased by 1463 patients between March 2020 and February 2021, compared with an average of 886 in 2019, and 765 in 2018. The likelihood of presenting with metabolic decompensation and severe diabetic ketoacidosis also significantly increased during this time.
Trump Officials Pushed for FDA Reauthorization of Hydroxychloroquine
Evidence from a congressional investigation revealed White House officials during Donald Trump’s presidency tried to push for the FDA reauthorization of a discredited COVID-19 treatment, hydroxychloroquine, The Associated Press reported. The FDA had originally authorized the use of hydroxychloroquine in late March 2020 based on small study results, at a time when researchers hoped existing antiviral drugs would work against the virus, but revoked its emergency use authorization 3 months later after it was found to be ineffective and potentially harmful. According to the report, the Trump administration attempted to control the release of FDA COVID-19 guidance and establish political operatives at public health agencies. There is no evidence that these efforts changed the FDA’s decisions on approving or rejecting hydroxychloroquine or any other therapies for COVID-19.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes
December 20th 2024Ian Neeland, MD, discusses the CINEMA program's impact on addressing social determinants of health (SDOH) in Ohio and the importance of precision risk tests to reduce cardiovascular metabolic disease risk.
Read More
